Name the product before judging the promise
Which drug, in which form, for which health concern? Ask for those details in plain words. “Peptide therapy” can leave them all open. An answer about a broad label is hard to check against a claim about a single product.
The federal medicine reviewer uses the initials FDA (Food and Drug Administration). A review concerns a named drug and use. Knowing only that a substance is a peptide leaves its status open.
FDA records checked November 3, 2026 show approval for these products. Tirzepatide (Mounjaro) helps manage type 2 diabetes; tirzepatide (Zepbound) is used for long-term weight control. Semaglutide (Ozempic) helps manage type 2 diabetes; semaglutide (Wegovy) is used for weight loss and keeping weight off. Each product’s label sets out who it is approved for and any other approved uses.
The FDA label for tirzepatide (Mounjaro) is a separate record. Match the name in a claim to the name in its supporting material, rather than treating familiar drug names as interchangeable.
Separate compounding from approval
To compound is to prepare a drug for a person’s needs. Under set rules, a pharmacist or doctor prepares it in place of a drug maker’s ready-made medicine.
FDA’s account, checked November 3, 2026, says compounded drugs do not have its approval. FDA has not checked their quality, how well they work or how safe they are before they are sold.
A named patient’s prescription
The name 503A comes from the part of federal law for compounding tied to a named patient’s prescription. That prescription alone does not meet all of the law’s conditions.
Other checks concern the raw active ingredient, the part that does the medicinal work. Where an official drug standard applies, the ingredient must meet it. With no such standard, the law asks whether the ingredient is in an approved drug. If neither path applies, the ingredient needs to be on the 503A ingredient list, the government’s extra list of ingredients allowed for this kind of compounding.
Federal law also restricts making regular copies of medicines already available. For that patient, the prescriber must judge whether the changed medicine makes a significant difference from the comparable ready-made drug.
A registered facility
The separate 503B route covers registered outsourcing facilities. These are places that make batches of sterile drugs, often for clinics. For these drugs, sterile means that living germs are absent.
In the state rules checked November 3, 2026, a retail pharmacy making sterile drugs also needs an Oklahoma sterile-compounding permit. That is an added permit, not approval of the peptide drug itself.
If compounding comes up in the visit, ask what need it would meet in your care. Put the pharmacy’s license in your notes, with the drug’s status on a separate line.
Keep the draft and the approval apart
The Department of Health and Human Services put forward a plan to hold back government action over certain compounded drugs. HHS is the department’s shortened name. The publication date of its draft is October 30, 2026. Such action is called enforcement: steps against a doctor or pharmacy for not meeting drug-law requirements. The department proposes this restraint for state-licensed doctors and pharmacies preparing a named patient’s prescription under its conditions. The peptide names in this plan are epitalon, MOTS-c, BPC-157, semax, TB-500 and KPV.
What the draft leaves out
The plan covers one peptide as the active drug ingredient, meaning the part doing the medicinal work. A blend of peptides falls outside it, as does compounding at a larger 503B facility. Its limits on routes concern how the drug enters the body, such as by injection. Appendix B limits each peptide’s form and route; the drug’s name alone cannot establish that a prescription fits.
This draft does not bind the agency or grant FDA approval. None of its six peptides is on the official 503A ingredient list. The draft describes choosing not to act under conditions; it does not change the ingredient law or create a right to compound.
The panel’s advice
HHS says the July 2026 advisory panel voted in favor of these six. It does not report totals showing how individual members voted. That missing detail does not change the legal position: the vote is advice, and changing the ingredient list requires a separate formal rule process.
For a proposed prescription, ask whether it names one patient, uses one peptide as the active ingredient, and comes from a state-licensed doctor or pharmacy. Ask the prescriber to show how its form and way of giving it fit the HHS draft and its appendices, and how all ten conditions are met. A plan about enforcement tells you what an agency may do; it does not approve the drug.
The groups seeking permission for these compounding ingredients later took their requests back. FDA’s ingredient page lists safety concerns beside BPC-157 and carries a page date of April 22, 2026. The words “current as of” date that page; FDA gives no date for each group’s decision to take a request back. Taking a request back does not clear the substance for use.
For BPC-157, FDA’s concerns include the body’s defenses reacting to peptide clumps or unwanted material in the drug. FDA also says it has little or no human safety information for the proposed ways of giving BPC-157, so it cannot tell whether those uses would cause harm.
Keep the source close to the claim
A useful answer names the product, identifies the source and explains what that source actually supports. Ask whether the evidence is about people using that exact product for that exact purpose. Keep an uncertainty in view rather than filling it with a hopeful conclusion.
“Research use only” says the product is a research supply, not a treatment for people. That wording does not cancel a sales page’s claims about treating people. The FDA warning letters reviewed for this chapter, checked November 3, 2026, treat these products as drugs for people despite their research labels.
For compounded weight-loss medicines, the FDA also identifies claims of sameness with an approved product as misleading.
Leave with a precise question
Ask the clinician, the person assessing or treating you, to connect the proposed medicine, your health concern and the evidence. If the answer rests on a draft policy, ask how its conditions apply to the actual prescription. Keep the distinction between permission, evidence and personal suitability in your notes.